Gill Heart Institute, University of Kentucky, Lexington, Kentucky.
Cardiothoracic Transplantation Programs, Newark Beth Israel Medical Center, Rutgers University-New Jersey Medical School, Newark, New Jersey.
J Am Coll Cardiol. 2019 Feb 19;73(6):698-716. doi: 10.1016/j.jacc.2018.11.038.
Venoarterial extracorporeal membrane oxygenation (ECMO) is a rescue therapy that can stabilize patients with hemodynamic compromise, with or without respiratory failure, for days or weeks. In cardiology, the main indications for ECMO include cardiac arrest, cardiogenic shock, post-cardiotomy shock, refractory ventricular tachycardia, and acute management of complications of invasive procedures. The fundamental premise underlying ECMO is that it is a bridge-to recovery, to a more durable bridge, to definitive treatment, or to decision. As a very resource- and effort-intensive intervention, ECMO should not be used on unsalvageable patients. As the use of this technology continues to evolve rapidly, it is important to understand the indications and contraindications; the logistics of ECMO initiation, management, and weaning; the general infrastructure of the program (including the challenges associated with transferring patients supported by ECMO); and ethical considerations, areas of uncertainty, and future directions.
静脉-动脉体外膜肺氧合(ECMO)是一种挽救性治疗方法,可在数天或数周内稳定伴有或不伴有呼吸衰竭的血流动力学不稳定的患者。在心脏病学中,ECMO 的主要适应证包括心脏骤停、心源性休克、心脏手术后休克、难治性室性心动过速以及侵入性操作并发症的急性处理。ECMO 的基本前提是它是一种恢复的桥梁,是更持久的桥梁,是明确的治疗方法,或者是决策的桥梁。作为一种非常耗费资源和精力的干预措施,ECMO 不应用于无法挽救的患者。随着这项技术的不断快速发展,了解适应证和禁忌证、ECMO 启动、管理和撤机的后勤工作、项目的一般基础设施(包括与 ECMO 支持的患者转院相关的挑战)以及伦理考虑、不确定性领域和未来方向非常重要。